Regeneron (REGN) Reports Dupixent Granted European Commission Approval for Adolescents with Moderate-to-Severe Atopic Sermatitis

August 6, 2019 5:57 AM
Renegeron (NASDAQ: REGN) announced the European Commission (EC) today extended the marketing authorization for Dupixent® (dupilumab) in the European Union ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Corporate News FDA Management Comments

Next Articles